{"news_desk": "SundayBusiness", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By KATIE THOMAS and GRETCHEN MORGENSON", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}, {"rank": 2, "role": "reported", "firstname": "Gretchen", "organization": "", "lastname": "MORGENSON"}]}, "abstract": "Future of Addyi, so-called 'female Viagra' approved by Food and Drug Admin to treat low sex drive in women, appears murky following manufacturer Valeant Pharmaceuticals' dismissal of product's entire sales force; drug firm has been besieged with internal problems and severe drop in stock price since it purchased Addyi's owner Sprout Pharmaceuticals for $1 billion in 2015.", "type_of_material": "News", "word_count": "2104", "lead_paragraph": "Missteps by Valeant, along with aggressive accounting practices and unusual business relationships, derailed one of the most intriguing drugs in a generation.", "pub_date": "2016-04-10T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "The Female Viagra, Undone by a Drug Maker\u2019s Dysfunction", "print_headline": "What Went Wrong for \u2018Female Viagra\u2019"}, "snippet": "Missteps by Valeant, along with aggressive accounting practices and unusual business relationships, derailed one of the most intriguing drugs in a generation.", "multimedia": [{"height": 126, "url": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbWide-v2.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbWide-v2.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 330, "url": "images/2016/04/10/business/10SPROUT/10SPROUT-articleLarge-v2.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "330", "xlarge": "images/2016/04/10/business/10SPROUT/10SPROUT-articleLarge-v2.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/04/10/business/female-viagra-addyi-valeant-dysfunction.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Addyi (Drug)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Sprout Pharmaceuticals Inc", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Philidor Rx Services LLC", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Ackman, William A", "name": "persons"}], "blog": [], "_id": "57092d4b38f0d84b5a70611c", "source": "The New York Times"}